For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Less goodwill impairment due to market capitalization | - | - | 3,200 | |
| Research and development | 0.426 | 0.297 | 0.48 | |
| General and administrative | 490.547 | 65.672 | 80.277 | |
| Total operating expenses | 490.973 | 65.969 | 3,280.757 | |
| Loss from operations | -490.973 | -65.969 | -3,280.757 | |
| Interest expense, net | 231.338 | 207.78 | 205.616 | |
| Loss on extinguishment / conversion of debt | - | 0 | - | |
| Change in fair value of derivative on debt | -392.058 | 484.198 | 114.722 | |
| Reimbursement for expenses - related party | - | 0 | - | |
| Total other expense | -623.396 | 276.418 | -90.894 | |
| Net loss before non-controlling interests | -1,114.369 | 210.449 | -3,371.651 | |
| Net loss attributable to non-controlling interests | -67.004 | -67.407 | -67.165 | |
| Net loss attributable to oncotelic therapeutics, inc | -1,047.365 | 277.856 | -3,304.486 | |
| Basic EPS | 0 | 0 | -0.01 | |
| Diluted EPS | - | 0 | -0.01 | |
| Basic Average Shares | 426,435,213 | 408,292,720 | 407,289,888 | |
| Diluted Average Shares | - | 452,809,058 | 407,289,888 | |
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)